Journal of Shandong University (Health Sciences) ›› 2020, Vol. 58 ›› Issue (12): 43-46.doi: 10.6040/j.issn.1671-7554.0.2020.0925

Previous Articles     Next Articles

Clinical observation of PEG-rhG-CSF in preventing neutropenia in 80 patients with small cell lung cancer treated with concurrent chemoradiotherapy

ZHANG Xiqin1,2, ZHU Shouhui2, LIU Ning2, WANG Yu2, CHEN Jiazhen2, HU Xudong2   

  1. 1. Shandong First Medical University, Jinan 250000, Shandong, China;
    2. Department of Radiation Oncology, Affiliated Cancer Hospital of Shandong First Medical University, Jinan 250117, Shandong, China
  • Published:2020-12-08

PDF (PC)

130

Abstract: Objective To investigate the preventive effect of pegylated recombinant human granulocyte colony stimulating factor(PEG-rhG-CSF)on neutropenia in patients with small cell lung cancer(SCLC). Methods A retrospective analysis of 80 SCLC cases(observation group)who received concurrent chemoradiotherapy and prophylactic use of PEG- rhG-CSF in Shandong Cancer Hospital was conducted, and 80 controls without useing PEG-rhG-CSF were matched according to age, gender and other factors. The neutropenia was observed and compared between the two groups. Results After concurrent chemoradiotherapy, the leukocytes count decreased in both groups, which was(3.15±0.76)×109 cells/L in the observation group and(1.82±0.77)×109 cells/L in the control group (Z=-8.467, P<0.001). Before chemoradiotherapy, there was no significant difference in the absolute value of neutrophils between the two groups(Z=-1.543, P=0.123). After chemoradiotherapy, the number of neutrophils decreased to(1.89±0.52)×109 cells/L in the observation group and(0.77±0.44)×109 cells/L in the control group. The decrease in the observation group was lower than that in the control group (Z=-10.034, P<0.001). Conclusion PEG-rhG-CSF can prevent the decrease of leukocytes and neutrophils, but experiments with larger samples are still needed for proof.

Key words: Pegylated recombinant human granulocyte colony stimulating factor, Small cell lung cancer, Concurrent radiotherapy and chemotherapy, Myelosuppression, Preventive effect

CLC Number: 

  • R734.2
[1] Cheng TY, Cramb SM, Baade PD, et al. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics [J]. J Thorac Oncol, 2016, 11(10): 1653-1671.
[2] 吴军, 杨小平. 分子靶向药物治疗非小细胞肺癌的研究进展[J]. 医学理论与实践, 2019, 32(10): 1489-1490. WU Jun, YANG Xiaoping. Advances in molecular targeting therapy for non-small cell lung cancer [J]. Medical Theory and Practice, 2019, 32(10): 1489-1490.
[3] 杨晨, 何小慧, 刘鹏, 等. 聚乙二醇化重组人粒细胞集落剌激因子预防化疗后中性粒细胞减少的有效性分析[J]. 中国肿瘤临床, 2015, 12(1): 626. YANG Chen, HE Xiaohui, LIU Peng, et al. Analysis of the efficacy of pegylated recombinant human granulocyte colony stimulating factor in the prevention of neutropenia after chemotherapy [J]. Chinese Oncology Clinic, 2015, 12(1): 626.
[4] 张冀伟. 聚乙二醇化重组人粒细胞集落刺激因子在预防小细胞肺癌化疗后中性粒细胞减少症的有效性分析[D]. 天津: 天津医科大学, 2018: 1-45.
[5] 许素真, 陈淑如. 重组人粒细胞集落刺激因子应用在乳腺癌化疗后骨髓抑制的预防效果分析[J]. 吉林医学, 2019, 40(3): 550-551. XU Suzhen, CHEN Shuru. Analysis of the preventive effect of recombinant human granulocyte colony stimulating factor on bone marrow suppression after breast cancer chemotherapy [J]. Jilin Medical Science, 2019, 40(3): 550-551.
[6] 莫红楠, 石远凯, 孙燕. 重组人粒细胞集落刺激因子在肿瘤化疗中应用 20 年回顾[J]. 中国新药杂志, 2013, 22(17): 2027. MO Hongnan, SHI Yuankai, SUN Yan. A 20-year review of the application of recombinant human granulocyte colony stimulating factor in tumor chemotherapy [J]. Chinese Journal of New Drugs, 2013, 22(17): 2027.
[7] 左金曼, 夏瑞祥. 重组人粒细胞集落刺激因子联合抗生素治疗急性白血病化疗后中性粒细胞缺乏合并感染患者的疗效[J]. 中国老年学杂志, 2016, 36(20): 5064-5066. ZUO Jinman, XIA Ruixiang. Efficacy of recombinant human granulocyte colony stimulating factor combined with antibiotics in the treatment of patients with neutropenia complicated with infection after chemotherapy in acute leukemia [J]. Chinese Journal of Gerontology, 2016, 36(20): 5064-5066.
[8] 陈琰, 陈坚, 张建华. 聚乙二醇化重组人粒细胞集落刺激因子在恶性肿瘤化疗后骨髓抑制患者中的应用[J].实用临床医药杂志,2019,23(23):61-63. CHEN Yan, CHEN Jian, ZHANG Jianhua. The application of pegylated recombinant human granulocyte colony-stimulating factor in patients with myelosuppression after chemotherapy of malignant tumor [J]. Journal of practical clinical medicine, 2019,23(23): 61-63.
[9] 范奎, 代良敏, 伍振峰, 等. 放化疗所致骨髓抑制的研究进展[J].中华中医药杂志,2017,32(1):210-214. FAN Kui, DAI Liangmin, WU Zhenfeng, et al. Progress in research on myelosuppression induced by chemoradiotherapy [J]. Chinese Journal of traditional Chinese medicine, 2017,32(1): 210-214.
[10] 宋君利, 陈明达, 艾建中, 等. PEG-rhG-CSF对以顺铂为基础联合化疗所致骨髓抑制的预防作用[J]. 实用癌症杂志,2017,32(10):1725-1727. SONG Junli, CHEN Mingda, AI Jianzhong,et al. The preventive effect of PEG- rhG- CSF on bone marrow suppression induced by cisplatin based chemotherapy [J]. Journal of practical cancer, 2017,32(10): 1725-1727.
[11] 贺晶晶, 高俊珍. 聚乙二醇化重组人粒细胞集落刺激因子的应用进展[J]. 国际呼吸杂志,2020,40(16):1255-1261. HE Jingjing, GAO Junzhen. Progress in the application of pegylated recombinant human granulocyte colony stimulating factor [J]. International Journal of respiration, 2020,40(16): 1255-1261.
[12] 李惠平, 樊征夫, 郑虹, 等. 聚乙二醇化重组人粒细胞集落刺激因子初级与次级预防化疗后中性粒细胞减少的有效性和安全性临床研究[J]. 中国肿瘤临床, 2019, 46(14): 739-744. LI Huiping, FAN Zhengfu, ZHENG Hong, et al. Clinical study on the efficacy and safety of pegylated recombinant human granulocyte colony stimulating factor in primary and Secondary prevention of neutropenia after chemotherapy [J]. Chinese Oncology Clinic, 2019, 46(14): 739-744.
[13] 张嘉扬, 刘雅昕, 王环, 等. 预防性应用长效粒细胞集落刺激因子在乳腺癌辅助化疗中的作用[J]. 中华医学杂志, 2018, 98(34): 2718-2721. ZHANG Jiayang, LIU Yaxin, WANG Huan, et al. Effect of prophylactic application of long-acting granulocyte colony stimulating factor in adjuvant chemotherapy for breast cancer [J]. Chinese Journal of Medicine, 2018, 98(34): 2718-2721.
[14] Shin KH, Lim KS, Lee H, et al. An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor(G-CSF), in healthy subjects [J]. Invest New Drugs, 2014, 32(4): 636‐643.
[15] 王海英, 刘莹, 胡盼, 李佳睿. 聚乙二醇化重组人粒细胞刺激因子预防老年恶性B细胞淋巴瘤化疗后中性粒细胞减少症的临床观察[J]. 中国老年学杂志, 2019, 39(24): 5961-5963. WANG Haiying, LIU Ying, HU Pan, et al. Clinical observation of pegylated recombinant human granulocyte stimulator in the prevention of neutropenia after chemotherapy for senile malignant B-cell lymphoma [J]. Chinese Journal of Gerontology, 2019, 39(24): 5961-5963.
[16] Pfeil AM, Allcott K, Pettengell R, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review [J].Support Care Cancer, 2015, 23(2): 525‐545.
[17] 蔡智慧, 田肖芳, 李蕾, 等. 聚乙二醇化重组人粒细胞集落刺激因子联合生血宝合剂预防恶性肿瘤化疗后骨髓抑制的临床观察[J]. 广西医学, 2020, 42(1): 21-23. CAI Zhihui, TIAN Xiaofang, LI Lei, et al. Clinical observation of pegylated recombinant human granulocytic colony stimulating factor combined with Shengxuebao Mixture in the Prevention of bone marrow suppression after chemotherapy for malignant Tumors [J]. Guangxi Medical Science, 2020, 42(1): 21-23.
[18] Xie J, Cao J, Wang JF, et al. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase Ⅲ study [J]. Breast Cancer Res Treat, 2018, 168(2): 389-399.
[1] LIU Xiaojing, XIA Xiyan, XIAO Ke, CHEN Wendan, ZHUANG Xuewei. Expression and clinical significance of exosomal long non-coding RNA OGFRP1 in 84 cases of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 71-75.
[2] ZENG Haiyan, LI Rui, SUN Xindong, XIE Peng, MENG Xue, FAN Bingjie, LI Wanlong, YUAN Shuanghu. Association analysis of brain metastases after prophylactic cranial irradiation in local disease small cell lung cancer: a bicenter study [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 61-66.
[3] SUN Qijing, CHEN Fangfang, LI Chunxiao, ZHANG Caiqing. Clinical value of PNI and HGB in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 55-59.
[4] PENG Yue, FENG Zhen, XIE Hounai, WANG Hui, LI Meng, REN Wangang, LIU Tong, PENG Zhongmin. Surgical treatment for 61 patients with multiple lung lesions [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(11): 42-46.
[5] WANG Lili, HUO Bin, WANG Lei, WANG Hao, HOU Dingkun, HUO Xiaodong, WANG Jinhuan, ZANG Li, CAO Qiang, CHAI Shude, WANG Haitao. Meta-analysis and system evaluation of 125I implantation in the treatment of early lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 76-83.
[6] ZHANG Zhiqiang, WU Yanhua, WANG Maoshui, WANG Xinfeng, WANG Yunshan. Diagnostic value of combination of PCT and NSE in serum for detecting small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(11): 36-39.
[7] GAO Ang, WANG Shijiang, FU Zheng, SUN Xindong, YU Jinming, MENG Xue. A feasibility study for boost target delineation using 18F-FDG PET/CT in local advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 73-77.
[8] DONG Jialiang, ZHANG Lei. Effect of cordycepin on the expression of CenpB of myelosuppression mice induced by cyclophosphamide [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 24-28.
[9] YANG Lu, LIU Yanguo, LI Jisheng, WANG Xiuwen. Effect of bufalin on chemosensitivity to cisplatin in non-small cell lung cancer and the underlying mechanisms [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(3): 6-11.
[10] GAO Peng, SHEN Fangzhen, XIAO Wenjing, XIU Yuande, ZHOU Lingling. Correlation between the expressions of Runx2 and Ezrin and postoperative metastasis in patients with stage IB non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(1): 63-66.
[11] YUAN Zhiping, MOU Huaping, CHEN Jialian, DENG Li. Expressions and significances of serum hepatic cancer-derived growth factor and vascular endothelial growth factor in patients with non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 63-66.
[12] ALIMUJIANG·Stiwaerdi, ZHANG Tao, PATIGULI·Aerxiding, LIU Li. Clinical analysis of recombinant human endostatin combined with gemcitabine and  cisplatin therapy in advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(3): 95-98.
[13] WANG Jian1, WANG Xiu-wen1, WANG Ya-wei1, MA Dao-xin2, WANG Pu3. Paclitaxel-octreotide conjugates inhibit growth of human  small cell lung cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(3): 27-32.
[14] WANG Jian1, WANG Xiu-wen1, WANG Ya-wei1, MA Dao-xin2, WANG Pu3. Paclitaxel-octreotide conjugates inhibit growth of human  small cell lung cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(3): 27-32.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd